All News

Three years after the FDA’s authority was broadened to allow it to require pharmaceutical manufacturers to conduct additional clinical studies or change medication labels (among other new powers), the FDA still has concerns about medication risks. Drug safety has always been an issue for the FDA, but given the recent high-profile troubles with the recalled painkiller Vioxx (rofecoxib), the contaminated blood-thinner heparin, and the sometimes fatal cardiac effects of the diabetes drug Avandia (rosiglitazone), it is clear to the FDA that it needs to have better oversight when it comes to medication safety.

Schizophrenia, a devastating mental illness that affects nearly 2.2 million Americans, is associated with high rates of morbidity and mortality.1 Persons with schizophrenia have a 20% shorter life expectancy than the general population.1,2 Furthermore, among persons with schizophrenia, there is an increased prevalence of metabolic syndrome characterized by a constellation of risk factors, including insulin resistance, abdominal obesity, dyslipidemia, hyperglycemia, and hypertension,3

As publicly funded health care payment programs have grown over decades because of demographic shifts and expansion of coverage, comparative effectiveness research (CER) has emerged to address value in health care. The American Recovery and Reinvestment Act of 2008 (ARRA) included $1.1 billion for CER initiatives, and the new health care legislation created the Patient-Centered Outcomes Research Institute, which will be funded with $500 million or more annually. In these efforts exist the promise to create informed decisions that will improve health care at both the individual and population levels.

A 20-month-old boy brought to the emergency department with swelling on the right side of the neck and fever (temperature, 39.3°C [102.7°F]) of 1 day’s duration. The parents reported that the child had had intermittent fevers and poor weight gain for the past 3 months but no vomiting, diarrhea, rash, drooling, or difficulty in swallowing.

A 14-year-old girl is seen because of long-standing nasal itch, intermittent nasal congestion, and clear nasal discharge. Allergies to house dust mites and to cats shown on prior skin testing. Often has marked eye swelling when exposed to cats. Receives antihistamines when in flare-up and prior to cat exposure. The consumption of dairy products exacerbates all of the above.

Medication adherence increased in patients who received a 90-day supply compared with those who received a 30-day supply, according to a recent presentation at the Academy of Managed Care Pharmacy’s Annual Meeting.

Many patients who take fish oil capsules complain of burping, which is often accompanied by an unpleasant fishy taste or odor.

Many pharmacological options exist for allergic rhinitis. Intranasal corticosteroids are the most effective medication class for patients with moderate to severe symptoms; those with milder intermittent symptoms can be treated with a second-generation oral or intranasal antihistamine.

How health reform imacts your practiceWhat provisions may have an immediate impact on your practice, and what to expect in the futureAMA

Health reform subsidy calculator: coverage in exchanges/gatewaysFor persons under age 65 who purchase coverage on their own and are not covered through their employer, Medicare or MedicaidKaiser Family Foundation

Call Me by My Name

I found “In Africa With the Pygmies” by Dr Scott Kellerman very moving.